Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Parent's Guide To Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month To Address Critical Education Gap
Expectant parents are poorly informed about cord blood banking, according to a study published in the Journal of Reproductive Medicine. In fact, of the expectant mothers in the study who indicated they have some knowledge of cord blood banking, 74 percent considered themselves minimally informed. Yet, the Institute of Medicine of the National Academy of Sciences recommends that all expectant parents should be educated about cord blood stem cells early enough in pregnancy that they can make an informed decision about the options to preserve these medically-beneficial cells.
generic viagra online
When A Dog Bites
A pet bites a child, and the owner is faced with an excruciating decision: Is it safe to keep this dog?
News of the day
What Is Diphtheria? What Causes Diphtheria?
Diphtheria is a bacterial infection in the upper respiratory tract. Typically it is characterized by sore throat, swollen neck glands, high temperature and breathing difficulties. Through means of successful immunization diphtheria is now very rare in the United States and Europe. However it"s still common in countries where immunization programs are not an integral part of standard public health care. It is a potentially fatal disease with an estimated 5-10% fatality rate. In children under 5 and adults over 40 the fatality rate may sometimes reach 20%.
Endocrinology

Significant Milestone Marks The Beginning Of FDA-Authorized Breast Cancer Trial

Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy. QI is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome." The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be targeted by the body"s own immune system) found in many tumor cell lines or fetal tissue, but absent on normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and promising antigen for individualized breast cancer immunotherapy. Centered in Mobile, AL, QI"s clinical trial is designed around the use of QI"s proprietary dendritic cell therapy, which employs OFA to recruit the patient"s own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient"s own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient"s T-cells will locate the OFA found on the patient"s cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease. About Quantum Immunologics Quantum Immunologics, Inc. ("QI") is a research-driven biotechnology company that is pioneering discoveries in immunotherapy science. QI is dedicated to the research, development and production of technologies that focus on the treatments and diagnoses of cancer and other diseases related to the immune system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI remains committed to advancing medicine with the ultimate goal of dramatically improving lives. Quantum Immunologics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009